Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Vose

Showing results (41-50 of 140) with videos related to

Pageof 14
Sort By:
Leukemia & Lymphoma|August 28, 1998
Lymphoma cells associated with bone marrow stromal cells in culture exhibit altered growth and survivalC D Weekes, S J Pirruccello, J M Vose, et al.
Leukemia & Lymphoma|August 10, 1999
Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experienceH Tezcan, J M Vose, M Bast, et al.
Journal of Hematotherapy|February 1, 1995
Autologous bone marrow transplantation for Hodgkin's diseaseJ O Armitage, P J Bierman, J M Vose, et al.
Cancer|January 1, 1992
Histologic grade does not predict prognosis in optimally treated, advanced-stage nodular sclerosing Hodgkin's diseaseA S Masih, D D Weisenburger, J M Vose, et al.
Journal of Hematotherapy|January 1, 1994
Detection of tumor contamination of peripheral stem cells in patients with lymphoma using cell culture and polymerase chain reaction technologyW C Chan, G Q Wu, T C Greiner, et al.
Leukemia & Lymphoma|July 27, 2016
Peripheral T-Cell Lymphoma-A Brief ReviewJ M Vose, D D Weisenburger, W G Sanger, et al.
American Journal of Clinical Oncology|December 1, 1991
Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphomaR M Bashir, P J Bierman, J M Vose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1991
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes AgressifsB Coiffier, C Gisselbrecht, J M Vose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphomaP J Bierman, J M Vose, J R Anderson, et al.
Leukemia & Lymphoma|October 21, 2005
Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphomaJ M Vose, B K Link, M L Grossbard, et al.
Pageof 14

Showing results (41-50 of 140) with videos related to

Sort By:
Pageof 14
Leukemia & Lymphoma|August 28, 1998
Lymphoma cells associated with bone marrow stromal cells in culture exhibit altered growth and survivalC D Weekes, S J Pirruccello, J M Vose, et al.
Leukemia & Lymphoma|August 10, 1999
Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experienceH Tezcan, J M Vose, M Bast, et al.
Journal of Hematotherapy|February 1, 1995
Autologous bone marrow transplantation for Hodgkin's diseaseJ O Armitage, P J Bierman, J M Vose, et al.
Cancer|January 1, 1992
Histologic grade does not predict prognosis in optimally treated, advanced-stage nodular sclerosing Hodgkin's diseaseA S Masih, D D Weisenburger, J M Vose, et al.
Journal of Hematotherapy|January 1, 1994
Detection of tumor contamination of peripheral stem cells in patients with lymphoma using cell culture and polymerase chain reaction technologyW C Chan, G Q Wu, T C Greiner, et al.
Leukemia & Lymphoma|July 27, 2016
Peripheral T-Cell Lymphoma-A Brief ReviewJ M Vose, D D Weisenburger, W G Sanger, et al.
American Journal of Clinical Oncology|December 1, 1991
Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphomaR M Bashir, P J Bierman, J M Vose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1991
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes AgressifsB Coiffier, C Gisselbrecht, J M Vose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphomaP J Bierman, J M Vose, J R Anderson, et al.
Leukemia & Lymphoma|October 21, 2005
Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphomaJ M Vose, B K Link, M L Grossbard, et al.
Pageof 14